View Older Stories View More Recent Stories

May 4, 2022 08:30AM Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
Apr 29, 2022 06:23PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 27, 2022 08:30AM Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
Mar 31, 2022 06:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 8, 2022 08:30AM Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program
Mar 2, 2022 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Mar 1, 2022 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
Feb 28, 2022 06:17PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 22, 2022 08:30AM Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
Feb 1, 2022 08:00AM Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
Jan 31, 2022 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 10, 2022 10:51AM Sarepta's (SRPT) Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for DMD
Jan 10, 2022 10:50AM Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatme
Jan 6, 2022 08:32AM Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 31, 2021 08:45PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2021 06:16PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 17, 2021 08:33AM Sarepta Therapeutics (SRPT) Appoints Stephen L. Mayo to its Board
Nov 17, 2021 08:32AM Sarepta Therapeutics (SRPT) Appoints Louise Rodino-Klapac as Head of Research and Development
Nov 17, 2021 08:31AM Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
Nov 17, 2021 08:30AM Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
Nov 3, 2021 04:01PM Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
Nov 2, 2021 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Oct 29, 2021 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 27, 2021 08:30AM Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
Oct 11, 2021 09:13AM Sarepta Therapeutics (SRPT) SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
Oct 11, 2021 09:13AM Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
Oct 4, 2021 04:30PM Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
Oct 4, 2021 07:00AM Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sep 30, 2021 07:06PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 27, 2021 08:30AM Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
Sep 14, 2021 08:30AM Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
Sep 7, 2021 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sep 7, 2021 08:30AM Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Aug 31, 2021 05:57PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2021 04:05PM Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
Aug 4, 2021 08:30AM Sarepta Therapeutics (SRPT) Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
Aug 4, 2021 08:30AM Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
Jul 30, 2021 05:42PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 28, 2021 08:30AM Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
Jun 30, 2021 06:40PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 3, 2021 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
May 28, 2021 06:55PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2021 08:51AM Sarepta Therapeutics (SRPT) Investigational Gene Therapy for Treatment of DMD, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
May 18, 2021 08:50AM Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commerci
May 17, 2021 04:07PM Sarepta Therapeutics (SRPT) to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of DMD
May 17, 2021 04:05PM Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
May 5, 2021 04:05PM Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
May 4, 2021 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
May 3, 2021 08:50AM Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021 08:50AM Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
View More Recent Stories View Older Stories